Abionyx Pharma Announces a Capital Increase of €18.7M and the Preparation of a €10M Bond Issue with Fenja Capital
French biopharmaceutical company Abionyx Pharma announced on Thursday the successful completion of its capital increase of €18.7M and the submission of a drawdown notice for a first bond tranche of €10M to benefit Danish fund Fenja Capital. This resource mobilization is intended to finance its clinical programs in sepsis and its regulatory progress on LCAT deficiency.
The capital increase of €18.7M, launched on May 27th, was fully covered through a combination of direct subscriptions and partially exercised guarantee commitments. It resulted in the issuance of 7,056,416 new shares at a price of €2.65 per share. Historical shareholders subscribed to about 40% of this increase by combining the exercise of their preemptive rights (exercise rate: 26.5%) and the partial implementation of guarantee commitments. The exercise rate of preemptive rights stood at 26.5%, supplemented by allocations on a reducible and free basis.
Fenja Capital II A/S, an independent investment fund based in Denmark, entered the capital as a new investor with an initial stake of 2.36% of the post-operation share capital. The settlement-delivery of the new shares will take place on June 22, 2026.
A €14M Bond Financing in Two Tranches
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In parallel, Abionyx submitted a drawdown notice for the first tranche of the bond financing amounting to €10M, scheduled for June 25, 2026. A second tranche of €4M may be drawn in the fourth quarter of 2026, subject to liquidity conditions and market capitalization. The bonds, with an interest rate of 3-month EURIBOR (floor of 2.00%) plus a 3.00% annual margin, must be repaid on May 26, 2028, with an option to extend until November 26, 2028. Fenja Capital also receives 2,240,424 free share subscription warrants (BSA), representing a potential dilution of 5.00% of the capital.
Resources Directed Towards Clinical Development and Regulatory Compliance
The net proceeds of the operation, estimated at €25.2M, will primarily finance two areas: €10M for the phase 2b clinical trial in sepsis (scheduled to start in 2026, with results expected by the end of the first half of 2028) and €9M for the advancement of the LCAT program towards a marketing authorization application (MAA) to the EMA at the beginning of 2028. The remainder is allocated to general needs and working capital. This operation extends the cash horizon until the third quarter of 2028, or until the fourth quarter of 2028 following the drawdown of the second bond tranche.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,9 millions d'euros
Quarterly revenue: 1,9 millions d'euros
Net income: -4,8 millions d'euros
-11,7 millions d'euros
Guidance from the release
« Le Groupe ayant réalisé en juin une opération de financement par augmentation de capital et dette obligataire simple (détaillé en Note O. « Dettes financières »), elle dispose d'une trésorerie suffisante pour faire face à ses besoins de trésorerie pendant au moins douze mois à compter de la date d'arrêté des comptes. »
Risks mentioned
Absence de revenu généré par l'activité biotech principale au T2 2026
Bioproduit fourni gratuitement dans le cadre des autorisations d'accès compassionnel, sans revenu associé
Dépendance du chiffre d'affaires consolidé à la seule filiale IRIS Pharma
Opportunities identified
Trésorerie de 26,9 M€ suite à l'opération de financement annoncée le 18 juin 2026
Visibilité financière étendue jusqu'à fin 2028
Chiffre d'affaires d'IRIS Pharma anticipé stable pour l'exercice 2026 par rapport à 2025
Outlook / guidance
Management commentary: « Based on the information available as of the date of this press release, the Company anticipates that IRIS Pharma's revenue for fiscal year 2026 will remain broadly stable compared to that of fiscal year 2025. »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
